Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Celgene MS drug clears...

    Celgene MS drug clears key trial, but disability data falls short

    Written by Ruby Khatun Khatun Published On 2017-05-23T09:07:33+05:30  |  Updated On 23 May 2017 9:07 AM IST
    Celgene MS drug clears key trial, but disability data falls short
    Celgene Corp's multiple sclerosis drug met the main goal of reducing annualized relapse rate, compared with Biogen Inc's Avonex, in a second late-stage trial, but failed to outperform Avonex in slowing disability progression rate.

    Celgene's shares fell as much as 2.8 percent to $113.63 in morning trading on Monday as investors focused on the disability data.


    The drug, ozanimod, was shown to be superior to Avonex in reducing annualized relapse rate in patients with relapsing multiple sclerosis (RMS) in another late-stage study in February.


    However, Celgene said on Monday a combined analysis of the two trials did not show ozanimod had a statistically significant benefit over Avonex in slowing disability progression.


    The company highlighted that overall the rate of disability progression was very low in the trials.


    Analysts did not read much into the data on disability progression, with Barclays calling it "only wrinkle" in the otherwise successful trials.


    With prior results suggesting a best-in-class profile, with Gilenya-like efficacy and absent heart rate effects, ozanimod has the advantage of a shorter half-life, a favorable feature highlighted by experts in terms of safety, Wells Fargo's Jim Birchenough said.


    Gilenya is a rival MS drug from Novartis AG.


    Ozanimod's adoption will depend on whether Gilenya goes generic in 2019, which may coincide with ozanimod's launch, Evercore ISI analyst Umer Raffat said.


    Ozanimod is expected to generate about $2 billion by 2022, according to Clarivate Analytics.


    Celgene, which gained access to ozanimod through its $7.2 billion acquisition of Receptos Inc in 2015, said it would file a U.S. marketing application for the drug by the end of the year.


    RMS is characterized by clearly defined attacks of worsening neurologic function.


    These attacks — often called relapses, flare-ups or exacerbations — are followed by partial or complete recovery periods during which symptoms improve partially or completely.


    Multiple sclerosis affects about 400,000 people in the United States and about 2.5 million people worldwide. About 85 percent are diagnosed with RMS, according to the company.


    The most popular MS treatment in the United States currently is Teva Pharmaceuticals Industries Ltd's Copaxone, which generated sales of about $4.22 billion in 2016.


    Celgene is also testing Ozanimod in ulcerative colitis and Crohn's disease.


    Up to Friday's close, Celgene had gained 17 percent in the past 12 months, outperforming the 9.6 percent rise in the Nasdaq Biotechnology Index during the same period.


    (Reporting by Divya Grover in Bengaluru; Editing by Sriraj Kalluvila)

    AvonexBiogen IncCelgene CorpGILENYAheart rateJim Birchenoughmultiple sclerosisMultiple Sclerosis DrugNovartis AGozanimodrelapsing multiple sclerosisUmer Raffat
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok